ES2131190T3 - Composicion que contiene efectores de circulacion mejorada y procedimiento de utilizacion de la indicada composicion. - Google Patents
Composicion que contiene efectores de circulacion mejorada y procedimiento de utilizacion de la indicada composicion.Info
- Publication number
- ES2131190T3 ES2131190T3 ES94910988T ES94910988T ES2131190T3 ES 2131190 T3 ES2131190 T3 ES 2131190T3 ES 94910988 T ES94910988 T ES 94910988T ES 94910988 T ES94910988 T ES 94910988T ES 2131190 T3 ES2131190 T3 ES 2131190T3
- Authority
- ES
- Spain
- Prior art keywords
- composition
- effectors
- procedure
- improved circulation
- indicated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Chemical And Physical Treatments For Wood And The Like (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/035,443 US6326353B1 (en) | 1993-03-23 | 1993-03-23 | Enhanced circulation effector composition and method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2131190T3 true ES2131190T3 (es) | 1999-07-16 |
Family
ID=21882712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES94910988T Expired - Lifetime ES2131190T3 (es) | 1993-03-23 | 1994-03-22 | Composicion que contiene efectores de circulacion mejorada y procedimiento de utilizacion de la indicada composicion. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6326353B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP0689428B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JPH08508256A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE175868T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU6368494A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2157410C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69416116T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0689428T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2131190T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1994021235A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| US6159460A (en) * | 1988-05-27 | 2000-12-12 | Amgen Inc. | Method for treating interleukin-1 mediated diseases |
| US6858409B1 (en) | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
| US6180134B1 (en) * | 1993-03-23 | 2001-01-30 | Sequus Pharmaceuticals, Inc. | Enhanced ciruclation effector composition and method |
| GB9509016D0 (en) * | 1995-05-03 | 1995-06-21 | Royal Free Hosp School Med | Tissue entrapment |
| US5919480A (en) * | 1996-06-24 | 1999-07-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal influenza vaccine composition and method |
| CA2273852C (en) | 1996-12-06 | 2009-09-29 | Amgen Inc. | Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |
| US5827533A (en) | 1997-02-06 | 1998-10-27 | Duke University | Liposomes containing active agents aggregated with lipid surfactants |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| CA2281794A1 (en) | 1997-02-21 | 1998-08-27 | Genentech, Inc. | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies |
| US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
| US6013253A (en) * | 1997-08-15 | 2000-01-11 | Amgen, Inc. | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
| US6458355B1 (en) | 1998-01-22 | 2002-10-01 | Genentech, Inc. | Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates |
| US6468532B1 (en) | 1998-01-22 | 2002-10-22 | Genentech, Inc. | Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
| US7005504B2 (en) | 1998-01-22 | 2006-02-28 | Genentech, Inc. | Antibody fragment-peg conjugates |
| CA2329768C (en) | 1998-04-27 | 2008-06-10 | Opperbas Holding B.V. | Pharmaceutical composition comprising factor viii and neutral liposomes |
| US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| US7829074B2 (en) | 2001-10-18 | 2010-11-09 | Nektar Therapeutics | Hydroxypatite-targeting poly(ethylene glycol) and related polymers |
| HUP0303616A3 (en) * | 2001-03-26 | 2006-07-28 | Alza Corp Mountain View | Liposome composition for improved intracellular delivery of a therapeutic agent |
| TR201809678T4 (tr) | 2001-06-26 | 2018-07-23 | Amgen Fremont Inc | Opgl ye karşi antikorlar. |
| US7771727B2 (en) * | 2002-03-01 | 2010-08-10 | The Administrators Of The Tulane Educational Fund | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
| MXPA05002514A (es) | 2002-09-06 | 2005-05-27 | Amgen Inc | Anticuerpo monoclonal anti-il-1r1 humano terapeutico. |
| US20040062748A1 (en) * | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| CA2510780A1 (en) * | 2002-12-19 | 2004-07-08 | Alza Corporation | Method of treating angiogenic tissue growth |
| ATE444984T1 (de) | 2002-12-31 | 2009-10-15 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
| US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| KR20060015534A (ko) | 2003-04-25 | 2006-02-17 | 더 펜 스테이트 리서치 파운데이션 | 성장 억제, 지질 유래된 생활성 화합물의 전신 전달을 위한방법 및 시스템 |
| WO2005014035A2 (en) * | 2003-08-08 | 2005-02-17 | Novo Nordisk Health Care Ag | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest |
| US7985417B2 (en) * | 2004-10-08 | 2011-07-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of lipid structure preparation |
| TW200618820A (en) * | 2004-11-05 | 2006-06-16 | Alza Corp | Liposome formulations of boronic acid compounds |
| WO2007005754A2 (en) * | 2005-07-01 | 2007-01-11 | Alza Corporation | Liposomal delivery vehicle for hydrophobic drugs |
| US8591457B2 (en) | 2005-08-10 | 2013-11-26 | Alza Corporation | Method for making a needle-free jet injection drug delivery device |
| JP2009507919A (ja) * | 2005-09-12 | 2009-02-26 | アルザ・コーポレーシヨン | 多発性骨髄腫を処置するためのリポソーム |
| AR056806A1 (es) | 2005-11-14 | 2007-10-24 | Amgen Inc | Moleculas quimericas de anticuerpo rankl- pth/ pthrp |
| WO2007133627A2 (en) * | 2006-05-10 | 2007-11-22 | Alza Corporation | Method for making liposomes conjugated with temperature-sensitive ligands |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| US8323635B2 (en) | 2007-11-14 | 2012-12-04 | General Regeneratives, Ltd. | Methods of using interleukin-1 receptor antagonist as a myeloprotective agent |
| MY171292A (en) | 2008-12-22 | 2019-10-07 | Creabilis S A | Synthesis of polymer conjugates of indolocarbazole compounds |
| TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
| CN101690801B (zh) | 2009-10-26 | 2012-08-01 | 上海交通大学 | 白细胞介素-1受体拮抗剂的用途及其药物组合物 |
| TWI397428B (zh) * | 2009-12-29 | 2013-06-01 | 財團法人工業技術研究院 | 標的第四介白素受體之傳輸系統 |
| DE102010043733A1 (de) | 2010-11-10 | 2012-05-10 | Oxprotect Gmbh | Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen |
| US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| EP2679236A1 (de) * | 2012-06-29 | 2014-01-01 | Zentrum für biomedizinische Technologie der Donau- Universität Krems | Dosierungsanleitung für endotoxinbindende Lipopeptide |
| WO2014050509A1 (ja) * | 2012-09-25 | 2014-04-03 | テルモ株式会社 | リポソームおよびリポソーム製剤 |
| EP2983721B2 (en) | 2013-04-12 | 2021-01-20 | Evox Therapeutics Limited | Therapeutic delivery vesicles |
| WO2015191783A2 (en) | 2014-06-10 | 2015-12-17 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| GB201417589D0 (en) | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
| US10041044B2 (en) | 2016-07-29 | 2018-08-07 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
| EP3836954B1 (en) | 2018-08-13 | 2025-05-07 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| CN111217993B (zh) * | 2018-11-26 | 2022-05-20 | 沈阳药科大学 | 一种聚乙二醇化酚红及其制备方法和用途 |
| US20250283174A1 (en) | 2022-05-16 | 2025-09-11 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4948590A (en) * | 1987-06-09 | 1990-08-14 | Yale University | Avidin or streptavidin conjugated liposomes |
| AU5858690A (en) * | 1989-06-14 | 1991-01-08 | Cetus Corporation | Polymer/antibiotic conjugate |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ES2077403T3 (es) * | 1991-02-14 | 1995-11-16 | Baxter Int | Procedimiento de microsuministro de farmacos utilizando liposomas bioadhesivos de farmacos. |
| JP3220180B2 (ja) * | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | 薬剤含有タンパク質結合リポソーム |
-
1993
- 1993-03-23 US US08/035,443 patent/US6326353B1/en not_active Expired - Lifetime
-
1994
- 1994-03-22 DE DE69416116T patent/DE69416116T2/de not_active Expired - Fee Related
- 1994-03-22 JP JP6521332A patent/JPH08508256A/ja active Pending
- 1994-03-22 WO PCT/US1994/003103 patent/WO1994021235A1/en not_active Ceased
- 1994-03-22 AU AU63684/94A patent/AU6368494A/en not_active Abandoned
- 1994-03-22 ES ES94910988T patent/ES2131190T3/es not_active Expired - Lifetime
- 1994-03-22 DK DK94910988T patent/DK0689428T3/da active
- 1994-03-22 CA CA002157410A patent/CA2157410C/en not_active Expired - Fee Related
- 1994-03-22 EP EP94910988A patent/EP0689428B1/en not_active Expired - Lifetime
- 1994-03-22 AT AT94910988T patent/ATE175868T1/de not_active IP Right Cessation
-
2004
- 2004-12-14 JP JP2004362085A patent/JP2005097320A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK0689428T3 (da) | 1999-09-13 |
| JP2005097320A (ja) | 2005-04-14 |
| CA2157410A1 (en) | 1994-09-29 |
| EP0689428B1 (en) | 1999-01-20 |
| ATE175868T1 (de) | 1999-02-15 |
| CA2157410C (en) | 1999-12-07 |
| WO1994021235A1 (en) | 1994-09-29 |
| JPH08508256A (ja) | 1996-09-03 |
| EP0689428A1 (en) | 1996-01-03 |
| DE69416116T2 (de) | 1999-06-24 |
| US6326353B1 (en) | 2001-12-04 |
| DE69416116D1 (de) | 1999-03-04 |
| AU6368494A (en) | 1994-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2147650T3 (es) | Dispositivo para la ablacion lineal de tejido endomiocardial con cateter de alta frecuencia. | |
| ES2173273T3 (es) | Articulo de tejido con indicador de extension. | |
| DK0689428T3 (da) | Forøget cirkulationseffektorpræparat og fremgangsmåde | |
| ES2136618T3 (es) | Cicatrizacion de heridas. | |
| ES2035259T5 (es) | Procedimiento para la fabricacion de un articulo absorbente. | |
| BR9910251A (pt) | Estimulação hematopoiética | |
| ES2167377T3 (es) | Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos. | |
| ES2156934T3 (es) | Compuestos que presentan una potente actividad de antagonistas del calcio y de antioxidantes y su utilizacion como agentes citoprotectores. | |
| ES2164708T3 (es) | Indicador biologico a base de bacillus circulans para esterilizadores gaseosos. | |
| AR002254A1 (es) | Formulacion antitrombotica y procedimiento para su manufactura | |
| ES2052277T3 (es) | Fibras de superficie especifica aumentada, un metodo para su fabricacion, pasta papelera esponjada que consiste en tales fibras y el uso de las fibras como material de absorcion. | |
| ES2129082T3 (es) | Espumas de gel de poliuretano hidrofilo, en especial para el tratamiento de heridas profundas, apositos basados en espumas de gel de poliuretano hidrofilo y procedimiento de obtencion. | |
| AR019309A1 (es) | Composicion de tenido para fibras queratinicas con un colorante directo cationico y un polimero sustantivo | |
| ES2149264T3 (es) | Agente terapeutico para el tratamiento de melanomas. | |
| ES2174465T3 (es) | Compuestos triazol y su utilizacion como ligandos de dopamina-d. | |
| ES2102514T3 (es) | Vendajes tubulares mejorados. | |
| CY1110288T1 (el) | Κολπικα χορηγουμενοι αντι-δυσρυθμικοι παραγοντες για την θεραπευτικη αντιμετωπιση της μητριαιας δυσρυθμιας | |
| ES2153820T3 (es) | Derivados de benzimidazol, procedimiento para su preparacion y aplicaciones. | |
| AR016798A1 (es) | Uso de una cepa de lactobacillus para la elaboracion de un medicamento | |
| ES2148414T3 (es) | Articulo absorbente sanitario. | |
| ES2036694T3 (es) | Procedimiento y dispositivo de desinfeccion de utensilios. | |
| ES2125696T3 (es) | Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales. | |
| ES2058656T3 (es) | 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-onas y su uso en la prevencion o tratamiento del sida. | |
| ES2166900T3 (es) | Derivados de ara-c. | |
| ES2086923T3 (es) | Procedimiento para mejorar la suavidad de un genero de algodon para toallas y tejidos relacionados sin perdida de resistencia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 689428 Country of ref document: ES |